Research shows that combining two blood-thinning drugs—rivaroxaban and aspirin—along with cholesterol-lowering statins and newer diabetes medications provides better protection against heart attacks and serious leg complications in peripheral artery disease patients. According to Gram Research analysis of the latest clinical evidence, this comprehensive approach targeting multiple disease pathways is more effective than older single-medication treatments, with semaglutide being the only weight-loss drug proven to reduce heart attacks in overweight patients without diabetes.
Peripheral artery disease (PAD) happens when blood vessels in the legs get clogged, similar to how arteries can clog in the heart. According to Gram Research analysis, this condition affects millions of people and increases the risk of heart attacks and leg complications. A new review in the European Heart Journal shows that doctors now have better ways to treat PAD using a combination of lifestyle changes and newer medications. The most promising approach combines two blood-thinning drugs—rivaroxaban and aspirin—along with cholesterol-lowering medicines and newer diabetes drugs that also protect the heart. These advances could help prevent serious complications and save lives.
Key Statistics
A 2026 review in the European Heart Journal found that dual therapy with low-dose rivaroxaban and aspirin reduces both cardiovascular events and serious limb complications more effectively than aspirin alone in high-risk peripheral artery disease patients.
According to the 2026 European Heart Journal review, semaglutide is the only anti-obesity medication demonstrated to reduce cardiovascular events in high-risk patients with overweight or obesity who don’t have diabetes.
The 2026 review identified that GLP-1 receptor agonists and SGLT2 inhibitors provide cardiovascular and kidney protection in peripheral artery disease patients independent of blood sugar control, with emerging evidence suggesting GLP-1 drugs may also reduce serious leg events.
Research analyzed in the 2026 European Heart Journal review shows that statins remain first-line therapy for all peripheral artery disease patients, with additional cholesterol-lowering agents like ezetimibe, bempedoic acid, and PCSK9 inhibitors needed when LDL cholesterol goals aren’t reached.
The Quick Take
- What they studied: How doctors can better treat peripheral artery disease (clogged blood vessels in the legs) using new medications and lifestyle changes to prevent heart attacks and leg problems.
- Who participated: This is a review article that analyzed existing research and treatment guidelines rather than studying specific patients directly.
- Key finding: A combination of two blood-thinning drugs (rivaroxaban and aspirin) works better than aspirin alone to prevent both heart attacks and serious leg complications in high-risk patients.
- What it means for you: If you have clogged leg arteries, your doctor may recommend newer medication combinations that are more effective than older treatments. Talk to your doctor about whether these options are right for your situation.
The Research Details
This is a comprehensive review article published in the European Heart Journal in 2026. Rather than conducting a new study with patients, the authors examined all the latest research and medical guidelines about treating peripheral artery disease. They looked at how different medications and lifestyle changes affect outcomes like heart attacks, strokes, and serious leg complications. The review focuses on understanding what causes PAD (problems with cholesterol, inflammation, blood clots, and metabolism) and how new treatments target these specific problems. By reviewing all available evidence, the authors created a guide for doctors on the best ways to treat different types of PAD patients.
This research approach is important because it brings together all the latest discoveries about PAD treatment in one place. Instead of doctors having to read hundreds of individual studies, this review helps them understand which treatments work best and how to combine them for each patient. The review also highlights that many people with PAD aren’t getting proper treatment, so understanding these advances could help more patients get better care.
This review was published in a top medical journal (European Heart Journal), which means it was reviewed by expert doctors before publication. The authors examined current treatment guidelines and recent clinical trials. However, because this is a review of existing research rather than a new study, the strength of any single recommendation depends on the quality of the studies it’s based on. The review identifies areas where more research is still needed.
What the Results Show
The review identifies several major advances in treating peripheral artery disease. First, combining two blood-thinning medications—low-dose rivaroxaban and aspirin—appears to be more effective than aspirin alone for preventing both heart attacks and serious leg complications in patients at high risk. This combination works best for patients who don’t have a high risk of bleeding. Second, cholesterol-lowering drugs called statins should be the first treatment for all PAD patients, and if they don’t lower cholesterol enough, doctors should add other medications like ezetimibe, bempedoic acid, or PCSK9 inhibitors. Third, newer diabetes medications—particularly GLP-1 receptor agonists (like semaglutide) and SGLT2 inhibitors—help protect the heart and kidneys even beyond their effects on blood sugar control. Semaglutide is the only weight-loss medication proven to reduce heart attacks in overweight or obese patients without diabetes.
The review emphasizes that treating PAD requires a complete approach combining lifestyle changes with medications. Quitting smoking, eating a healthy diet, and regular physical activity are essential parts of treatment. The authors also stress that many people with PAD aren’t being diagnosed or treated properly, suggesting there’s a gap between what doctors know works and what patients actually receive. The review proposes a new way to categorize PAD patients based on their individual risk factors, which could help doctors choose more personalized treatments.
These findings represent significant progress from older PAD treatment approaches. Previously, doctors mainly used aspirin alone for blood clotting prevention and older cholesterol medications. The newer combination therapies and medications discussed in this review are based on recent clinical trials showing better outcomes. The emphasis on using newer diabetes drugs for heart protection is relatively new—these medications were originally developed for diabetes but have been found to help even non-diabetic patients with PAD. This represents a shift toward treating the underlying causes of PAD rather than just managing symptoms.
As a review article rather than a new clinical trial, this work depends on the quality of studies it examines. Some newer treatments may not have long-term data yet. The review doesn’t provide specific numbers on how many patients benefit from each treatment because it’s synthesizing many different studies with different patient populations. Individual patients may respond differently to treatments, so recommendations need to be personalized by doctors. More research is still needed on some of the newer medication combinations, particularly regarding long-term safety and effectiveness.
The Bottom Line
If you have peripheral artery disease, work with your doctor on a complete treatment plan including: (1) quitting smoking if applicable, (2) eating a heart-healthy diet, (3) regular physical activity as tolerated, (4) taking a statin for cholesterol, (5) considering the combination of rivaroxaban and aspirin if you’re at high risk and don’t have high bleeding risk, and (6) discussing newer diabetes or weight-loss medications if appropriate. These recommendations have strong evidence from multiple studies. The confidence level is high for statins and lifestyle changes, moderate-to-high for the blood-thinner combination, and moderate for newer diabetes medications in non-diabetic patients.
Anyone diagnosed with peripheral artery disease should discuss these advances with their doctor. People with risk factors for PAD (smoking, diabetes, high cholesterol, high blood pressure, or family history) should also be aware of these treatments. These recommendations are particularly important for people at high risk of heart attacks or serious leg complications. People with active bleeding problems or very high bleeding risk should discuss the blood-thinner combination with their doctor before starting it.
Lifestyle changes like quitting smoking and increasing activity can show benefits within weeks to months. Cholesterol-lowering medications typically take 4-12 weeks to show their full effect. Blood-thinning medications work immediately to reduce clot risk. Newer diabetes medications may take several months to show cardiovascular benefits. Most patients need to stay on these treatments long-term to maintain protection.
Frequently Asked Questions
What is peripheral artery disease and why is it dangerous?
Peripheral artery disease occurs when blood vessels in the legs become clogged with fatty deposits, reducing blood flow. It increases the risk of heart attacks, strokes, and serious leg complications including tissue damage and amputation. Many people have PAD without knowing it, making early detection and treatment important.
What medications are now recommended for treating peripheral artery disease?
Current treatment combines statins for cholesterol, aspirin, and often rivaroxaban (a blood thinner). Newer options include GLP-1 receptor agonists like semaglutide and SGLT2 inhibitors, which protect the heart and kidneys. Your doctor will personalize recommendations based on your individual risk factors and medical history.
Can lifestyle changes alone treat peripheral artery disease?
Lifestyle changes are essential but usually not enough alone. Quitting smoking, regular walking, a healthy diet, and weight loss are critical components of treatment. However, most PAD patients also need medications like statins and blood thinners to prevent serious complications like heart attacks and leg damage.
Is the combination of rivaroxaban and aspirin safe for everyone with PAD?
The rivaroxaban and aspirin combination works best for patients at high risk of heart attacks or leg complications who don’t have a high bleeding risk. People with active bleeding, certain bleeding disorders, or those taking other blood thinners need to discuss this combination carefully with their doctor before starting.
How long does it take to see benefits from PAD medications?
Blood thinners work immediately to reduce clot risk. Cholesterol medications take 4-12 weeks to show full effect. Lifestyle changes like quitting smoking show benefits within weeks to months. Most patients need to continue these treatments long-term to maintain heart and leg protection.
Want to Apply This Research?
- Track daily steps or walking distance (in minutes), weekly smoking status, and monthly cholesterol levels if available. Monitor any leg pain, numbness, or difficulty walking, noting when symptoms occur and what activities trigger them.
- Set a daily walking goal starting with 10-15 minutes and gradually increase. Log medication adherence daily, especially blood-thinners and cholesterol medications. Record dietary choices focusing on heart-healthy foods and sodium intake. Track smoking cessation milestones if applicable.
- Weekly check-ins on medication adherence and activity levels. Monthly reviews of leg symptoms and walking capacity. Quarterly tracking of weight and diet quality. Prepare a summary of these metrics to share with your doctor at each visit to help adjust treatment as needed.
This article summarizes a medical review and should not replace professional medical advice. Peripheral artery disease is a serious condition requiring individualized treatment by a qualified healthcare provider. The medications and treatments discussed—including rivaroxaban, aspirin combinations, and newer diabetes medications—carry specific risks and benefits that must be evaluated for your personal situation. Do not start, stop, or change any medications without consulting your doctor. If you have symptoms like leg pain during walking, numbness, or wounds that won’t heal, seek immediate medical attention. This information is current as of July 2026 and medical recommendations may evolve.
This research translation is published by Gram Research, the science division of Gram, an AI-powered nutrition tracking app.